On 22 September 2008, orphan designation (EU/3/08/571) was granted by the European Commission to ADIENNE S.r.l., Italy, for recombinant human minibody against complement component C5 for the treatment of atypical haemolytic uraemic syndrome (aHUS) associated with an inherited abnormality of the complement system.
Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in April 2019 on request of the Sponsor.
In January 2014, ADIENNE S.r.l. changed name to ADIENNE S.r.l.S.U.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
EU/3/08/571: Public summary of positive opinion for orphan designation of recombinant human minibody against complement component C5 for the treatment of atypical haemolytic uraemic syndrome (aHUS) associated with an inh... (PDF/151.85 KB)
First published: 02/04/2009
Last updated: 22/01/2014
Recombinant human minibody against complement component C5
|Disease / condition||
Treatment of atypical haemolytic uraemic syndrome (aHUS)
|Date of decision||
|Orphan decision number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases which includes a directory of patients' organisations registered in Europe.European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.